Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations

Charles A. Kunos, Evanthia Galanis, Jeffrey Buchsbaum, Qian D Shi, Lewis C. Strauss, C. Norman Coleman, Mansoor M. Ahmed

Research output: Contribution to journalArticle


Glioblastoma is an aggressive disease characterized by moderate initial response rates to first-line radiation–chemotherapy intervention followed by low poor response rates to second-line intervention. This article discusses novel strategic platforms for the development of radiation–investigational agent combination clinical trials for primary and recurrent glioblastoma in a NCI-NCTN settings with simultaneous analysis of challenges in the drug development process.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalJournal of Neuro-Oncology
StateAccepted/In press - May 30 2017



  • Cancer discovery
  • Clinical cancer research
  • Clinical trials
  • Experimental chemotherapy
  • Precision medicine
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this